Cite
HARVARD Citation
You, B. et al. (n.d.). 36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study. International journal of gynecological cancer. pp. A24-A25. [Online].